**Supplementary Table 1:** Univariate regression analysis of survival of patients with glioblastoma censored at different times of follow-up.

| Variable | Censored at 180 days | Censored at 250 days | Censored at 365 days | Censored at 730 days |
|----------|----------------------|----------------------|----------------------|----------------------|
|          | HR | lower | upper | p | HR | lower | upper | p | HR | lower | upper | p | HR | lower | upper | p |
| ↑Asc     | 0.093 | 0.012 | 0.743 | **0.025** | 0.133 | 0.029 | 0.610 | **0.009** | 0.467 | 0.199 | 1.098 | 0.081 | 0.555 | 0.276 | 1.116 | 0.098 |
| ↓HIF    | 0.144 | 0.030 | 0.697 | **0.016** | 0.152 | 0.041 | 0.566 | **0.005** | 0.463 | 0.198 | 1.080 | 0.075 | 0.392 | 0.188 | 0.818 | **0.013** |
| Age      | 1.071 | 0.999 | 1.147 | 0.053 | 1.069 | 1.009 | 1.134 | **0.025** | 1.037 | 0.997 | 1.079 | 0.070 | 1.010 | 0.978 | 1.043 | 0.535 |
| Sex      | 0.479 | 0.129 | 1.785 | 0.273 | 0.362 | 0.117 | 1.125 | 0.079 | 0.606 | 0.254 | 1.448 | 0.260 | 0.537 | 0.254 | 1.136 | 0.104 |
| IDH1     | 1.3E-08 | 0 | Inf | 1.3E-08 | 0 | Inf | 0.998 | 0.469 | 0.063 | 3.489 | 0.459 | 0.660 | 0.157 | 2.779 | 0.571 |
| Rad      | 0.131 | 0.034 | 0.501 | **0.003** | 0.107 | 0.031 | 0.363 | **0.0003** | 0.107 | 0.031 | 0.363 | **0.0003** | 0.107 | 0.031 | 0.363 | **0.0003** |
| Chemo    | 3.3E-10 | 0 | Inf | 0.999 | 0.046 | 0.006 | 0.361 | **0.003** | 0.214 | 0.087 | 0.532 | **0.001** | 0.218 | 0.097 | 0.490 | **0.0002** |
| Therapy  | 0.078 | 0.020 | 0.309 | **0.0003** | 0.078 | 0.020 | 0.309 | **0.0003** | 0.078 | 0.020 | 0.309 | **0.0003** | 0.078 | 0.020 | 0.309 | **0.0003** |

Asc, ascorbate; HIF, hypoxia inducible factor 1 pathway; Rad, radiation therapy; chemo, temozolomide chemotherapy; Therapy, all: radiation, chemotherapy and chemoradiation; HR, hazard ratio; lower and upper, 95% confidence intervals from Cox regression analysis.
## Supplementary Table 2: Univariate and multivariate analysis of glioblastoma survival censored at 250 days.

| Variable | Univariate | Adjusted for Age | Adjusted for Treatment | Adjusted for Age + Treatment |
|----------|------------|------------------|------------------------|-----------------------------|
|          | HR    | lower | upper | p   | HR    | lower | upper | p   | HR    | lower | upper | p  | HR    | lower | upper | p  |
| ↑Asc     | 0.133 | 0.029 | 0.610 | **0.009** | 0.167 | 0.036 | 0.780 | **0.023** | 0.214 | 0.043 | 1.066 | 0.060 | 0.244 | 0.049 | 1.229 | 0.087 |
| ↓HIF     | 0.152 | 0.041 | 0.566 | **0.005** | 0.139 | 0.036 | 0.532 | **0.004** | 0.255 | 0.061 | 1.068 | 0.062 | 0.207 | 0.048 | 0.893 | **0.035** |
| Age      | 1.069 | 1.009 | 1.134 | **0.025** | 1.054 | 0.987 | 1.127 | 0.117 | 1.054 | 0.987 | 1.127 | 0.117 | 1.054 | 0.987 | 1.127 | 0.117 |
| Sex      | 0.362 | 0.117 | 1.125 | 0.079 | 0.310 | 0.096 | 0.996 | **0.049** | 0.509 | 0.156 | 1.659 | 0.262 | 0.430 | 0.127 | 1.456 | 0.175 |
| IDH1     | 1.3E-08 | 0 | Inf | 0.998 | 4.5E-08 | 0 | Inf | 0.998 | 7.8E-09 | 0 | Inf | 0.999 | 2.0E-08 | 0 | Inf | 0.999 |
| Rad      | 0.107 | 0.031 | 0.363 | **0.000** | 0.114 | 0.032 | 0.403 | **0.001** | 0.114 | 0.032 | 0.403 | **0.001** | 0.114 | 0.032 | 0.403 | **0.001** |
| Chemo    | 0.046 | 0.006 | 0.361 | **0.003** | 0.053 | 0.007 | 0.423 | **0.006** | 0.053 | 0.007 | 0.423 | **0.006** | 0.053 | 0.007 | 0.423 | **0.006** |
| Therapy  | 0.078 | 0.020 | 0.309 | **0.000** | 0.107 | 0.026 | 0.438 | **0.002** | 0.107 | 0.026 | 0.438 | **0.002** | 0.107 | 0.026 | 0.438 | **0.002** |

Asc, ascorbate; HIF, hypoxia inducible factor 1 pathway; Rad, radiation therapy; chemo, temozolomide chemotherapy; Therapy, all: radiation, chemotherapy and chemoradiation; HR, hazard ratio; lower and upper, 95% confidence intervals from Cox regression analysis.